Cellectis

Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million

Retrieved on: 
Tuesday, April 4, 2023
Exercise, Tranche, BofA Securities, Finance, UCART123, AP, Person, Sale, Warrant, CAR, Euronext, Form 6-K, EIB, European Investment Bank, EB, Commercial code, Security (finance), Cellectis

The Company also announced the drawdown of the first tranche of €20 million (“Tranche A”) under the Finance Contract, expected to be disbursed by the EIB in early April 2023.

Key Points: 
  • The Company also announced the drawdown of the first tranche of €20 million (“Tranche A”) under the Finance Contract, expected to be disbursed by the EIB in early April 2023.
  • of the French Commercial Code, representing 5.0% of the Company’s outstanding share capital as at their issuance date.
  • The EIB Warrants with respect to Tranche B and Tranche C are only issuable if the Company elects to drawdown such tranches.
  • The Warrant Agreement contains certain customary representations and warranties by the Company and is governed by French law.

Celyad Oncology appoints Georges Rawadi as its new CEO

Retrieved on: 
Friday, March 24, 2023
Interim, Business development, Chairperson, Doctor of Philosophy, Intellectual property, Research, IP, Executive master's degree, CAR, Euronext, Growth, Health Industry Business Communications Council, BD, Management, Nursing, Microbiology, Cellectis, Biochemistry

Georges Rawadi is a seasoned executive with over 20 years of experience in pharma/biotech, as research director, business developer, CEO and board member.

Key Points: 
  • Georges Rawadi is a seasoned executive with over 20 years of experience in pharma/biotech, as research director, business developer, CEO and board member.
  • Georges Rawadi currently holds a number of Board positions and consultancy roles in the biotechnology industry.
  • Recently, he has served as CEO and Board member of Ysopia Bioscience (France), Vice-President BD & IP of Celyad Oncology and Vice-President Business Development of Cellectis (France - Nasdaq listed company).
  • We look forward to work with Georges in monetizing our IP and research assets, ensuring that Celyad Oncology can make an impact on a global scale.”

Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, March 14, 2023
Tumor microenvironment, AACR, MUC1, Annual general meeting, Prognosis, CAR, Senior, TGFB1, Patient, Triple-negative breast cancer, Breast, TNBC, TME, Euronext Growth, American Association for Cancer Research, Vaccine, Medical imaging, Cellectis

“As immune-therapies continue to develop for solid tumors, the tumor microenvironment (TME) poses many challenges that CAR T-cells need to overcome for efficient tumor cell clearance.

Key Points: 
  • “As immune-therapies continue to develop for solid tumors, the tumor microenvironment (TME) poses many challenges that CAR T-cells need to overcome for efficient tumor cell clearance.
  • Tumor-associated MUC1 antigen is overexpressed in a large number of TNBC patients offering an effective discriminatory target for CAR T-cell therapy.
  • Cellectis will present innovative strategies exploring purposeful armoring of CAR T-cells to boost efficiency while preserving safety.
  • The recirculation pattern of MUC1 CAR T-cells was also explored in relationship with their delivery routes.

Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, March 6, 2023
Tripura Merger Agreement, Register, Science, CBUS, Synthetic biology, Biotechnology, Form, Registration statement, Palm oil, Three Months, Gesellschaft mit beschränkter Haftung, PCM, Corporation, Euronext Growth, Agriculture, Biofactories, Cellectis, Prospectus, Airline, Video game, Fine chemical, Cryptocurrency, Transition

As a result of the settlement, Calyxt received $750 thousand in the fourth quarter of 2022 and received another $750 thousand earlier in the first quarter of 2023.

Key Points: 
  • As a result of the settlement, Calyxt received $750 thousand in the fourth quarter of 2022 and received another $750 thousand earlier in the first quarter of 2023.
  • Financial Results for the Three Months Ended December 31, 2022
    Cash, cash equivalents, and restricted cash totaled $3.5 million as of December 31, 2022.
  • Revenue was nominal in the fourth quarter of 2022 compared to $1.9 million in the fourth quarter of 2021.
  • Total operating expenses were $3.4 million in the fourth quarter of 2022 compared to $6.6 million in the fourth quarter of 2021.

Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023

Retrieved on: 
Wednesday, March 1, 2023
Euronext, Pharmaceutical industry, Mobile phone, Cellectis

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and year-end 2022 ending December 31st, 2022, on Wednesday, March 8, 2023, after the close of the US market.

Key Points: 
  • NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and year-end 2022 ending December 31st, 2022, on Wednesday, March 8, 2023, after the close of the US market.
  • The announcement will be followed by a conference call and live audio webcast on Thursday, March 9, 2023, at 8:00 AM ET / 2:00 PM CET.
  • The call will include the Company’s fourth quarter results, year-end results, and an update on business activities.
  • Details for the call are as follows:

Global TIL Therapies Market Report 2023 to 2035: Key Players Include Bristol-Myers Squibb, CAR-T (Shanghai) Cell Biotechnology, Cellectis and Incyte - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 1, 2023
Biotechnology, Pharmaceutical, Health, TILS, Investment, Cellectis, Head, Melanoma, Lymphocyte, Nature, NK, Macrophage, Patient, Clinical trial, Moving target indication, Neoplasm, USD, Mayo Collaborative Services v. Prometheus Laboratories, Inc., Growth, TIL, Bristol Myers Squibb, Antigen, Phio Pharmaceuticals, Cancer, Sales, Medical imaging, Pharmaceutical industry

The "Global TIL Therapies Market : Distribution by Target Indication, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global TIL Therapies Market : Distribution by Target Indication, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.
  • The report features an extensive study of the current market landscape and future opportunity for the players focused on the development of TIL therapies.
  • This report features an extensive study of the current market landscape and future opportunity for the players focused on the development of TIL therapies.
  • Overall, we are led to believe that the global TIL therapies market is poised to witness significant growth in the foreseen future.

Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Wednesday, February 8, 2023
Telephone, Barclays Capital Inc. v. Theflyonthewall.com, Inc., Bloomberg, Attention, Broadridge Financial Solutions, Security (finance), Jefferies Group, ADSS, Government, Madison Avenue, Sale, American depositary receipt, Additional notification thresholds, Euronext Growth, European Investment Bank, Risk, Form, Prospectus, Exercise, Annual report, Lender option borrower option, Cellectis, Option

The Additional ADSs will be listed on the Nasdaq Global Market under the symbol “CLLS”, and the Company’s Additional Ordinary Shares will be listed on Euronext Growth in Paris under the symbol “ALCLS”.

Key Points: 
  • The Additional ADSs will be listed on the Nasdaq Global Market under the symbol “CLLS”, and the Company’s Additional Ordinary Shares will be listed on Euronext Growth in Paris under the symbol “ALCLS”.
  • The closing of the Option is expected to occur on February 8, 2023, subject to customary closing conditions.
  • Jefferies LLC and Barclays Capital Inc. acted as joint book-running managers for the Global Offering.
  • The partial exercise of the Option is part of stabilization activities carried out since the announcement of Cellectis' Global Offering.

Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information

Retrieved on: 
Friday, February 3, 2023
Cellectis, Telephone, Council, Barclays Capital Inc. v. Theflyonthewall.com, Inc., Attention, Broadridge Financial Solutions, Security (finance), European Parliament, Jefferies Group, ADSS, Madison Avenue, Offering, ADS, Securities market participants (United States), Sale, European, Union, Baillie Gifford, ISIN, Euronext Growth, Risk, Prospectus, Annual report, Form, MAR, EU

The ADSs are being offered pursuant to an effective shelf registration statement on Form F-3 (Registration No.

Key Points: 
  • The ADSs are being offered pursuant to an effective shelf registration statement on Form F-3 (Registration No.
  • The Global Offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement.
  • In particular, no public offering of the ADSs will be made in the European Union or any of its member states.
  • These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management.

Cellectis Announces Pricing of Follow-On Offering

Retrieved on: 
Friday, February 3, 2023
Telephone, Council, Barclays Capital Inc. v. Theflyonthewall.com, Inc., Bloomberg, Attention, Broadridge Financial Solutions, Security (finance), European Parliament, Jefferies Group, ADSS, Government, Madison Avenue, Offering, ADS, Sale, European, Union, American depositary receipt, ISIN, Euronext Growth, European Investment Bank, Risk, Form, Prospectus, Exercise, Annual report, Lender option borrower option, MAR, Cellectis, EU

The aggregate net proceeds to be received by Cellectis from the sale of ADSs in the Global Offering are expected to be approximately $20.2 million, equivalent to approximately €18.5 million, after deducting the estimated expenses related to the Global Offering and the underwriting commissions payable by Cellectis.

Key Points: 
  • The aggregate net proceeds to be received by Cellectis from the sale of ADSs in the Global Offering are expected to be approximately $20.2 million, equivalent to approximately €18.5 million, after deducting the estimated expenses related to the Global Offering and the underwriting commissions payable by Cellectis.
  • The closing of the Global Offering is expected to occur on or about February 7, 2023, subject to customary closing conditions.
  • Jefferies LLC and Barclays Capital Inc. are acting as joint book-running managers for the Global Offering.
  • In connection with the Global Offering, Cellectis granted Jefferies LLC and Barclays Capital Inc. (the “Underwriters”) a 30-day option to purchase up to an additional 1,320,000 ADSs representing 15% of the Global Offering size and on the same terms and conditions.

Cellectis Announces Launch of Follow-On Offering

Retrieved on: 
Thursday, February 2, 2023
Telephone, EDGAR, Council, Barclays Capital Inc. v. Theflyonthewall.com, Inc., Attention, Broadridge Financial Solutions, Security (finance), European Parliament, Jefferies Group, ADSS, Madison Avenue, ADS, Sale, European, American depositary receipt, UCART123, Commercial code, Euronext Growth, Form, Conseil, Prospectus, MAR, Cellectis, EU

NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced the launch of a global offering of USD 22 million of its American Depositary Shares (“ADS”), each representing one ordinary share of Cellectis, nominal value €0.05 per share (the “Global Offering”) pursuant to an underwriting agreement, to be entered into by Cellectis, Jefferies LLC and Barclays Capital Inc.

Key Points: 
  • NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced the launch of a global offering of USD 22 million of its American Depositary Shares (“ADS”), each representing one ordinary share of Cellectis, nominal value €0.05 per share (the “Global Offering”) pursuant to an underwriting agreement, to be entered into by Cellectis, Jefferies LLC and Barclays Capital Inc.
  • Jefferies LLC and Barclays Capital Inc. (the “Underwriters”) are acting as joint book-running managers for the Global Offering.
  • The Global Offering is subject to market and other conditions and the final aggregate amount of the Global Offering is subject to change.
  • In particular, no public offering of the ADSs will be made in Europe.